Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q1 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $48.3 million versus the consensus estimate of $51.17 million.

Kiniksa now expects ARCALYST net product revenue for the full-year 2023 of between $200 million and $215 million.
Kiniksa now expects that its cash and cash equivalents will fund its current operating plan into at least 2026.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.